Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today issued the following statement:
納特拉公司（納斯達克：NTRA）是全球電芯DNA和基因檢測領域的領導者，今天發表了以下聲明：
In 2021, Natera and Guardant Health filed false advertising cases against each other concerning statements both companies made more than three years ago about Guardant's Reveal test. Today, a jury issued a decision in Guardant's favor. We disagree with this decision and will ask the Court to overturn it.
2021年，Natera和guardant health針對彼此提起虛假廣告訴訟，涉及兩家公司三年前關於Guardant的Reveal測試所做的聲明。今天，陪審團做出了支持Guardant的決定。我們對這個決定持不同意見，並將要求法院撤銷該決定。
The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant's Reveal test. This case had nothing to do with the validity or utility of Signatera, and certain key pieces of evidence supporting Natera's case were not included in this trial.
陪審團被要求評估2021年短暫時間內播出的與Guardant的Reveal測試性能有關的比較廣告。此案與Signatera的有效性或實用性無關，並且支持Natera案件的某些關鍵證據並未納入此次審判。
In the years that have passed since these events, Signatera has become the most widely used MRD test in the U.S., extensively validated with published evidence in more than 100 peer-reviewed papers across multiple cancer types and indications.
自這些事件發生以來的幾年時間裏，Signatera已成爲美國最廣泛使用的MRD測試，經過豐富的驗證，並在100多篇同行評議文獻中以多種癌症類型和適應症進行了發表。
譯文內容由第三人軟體翻譯。
